Download PDF
Z Gastroenterol 2015; 53(08): 774-778
DOI: 10.1055/s-0035-1553499
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Geschlechtsspezifische Unterschiede in der Behandlungsrealität von Patientinnen und Patienten mit chronisch-entzündlichen Darmerkrankungen (CED)

Gender differences and inflammatory bowel disease
J. Hausmann
,
I. Blumenstein
Further Information

Publication History





Publication Date:
18 August 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die vorliegende Übersichtsarbeit gibt einen Überblick über die aktuelle Studienlage zu geschlechtsspezifischen Unterschieden in der Behandlungsrealität von Patienten mit chronisch-entzündlichen Darmerkrankungen (CED). Dabei wird auf den Krankheitsverlauf, die medikamentöse und chirurgische Therapie ebenso wie auf die psychosozialen Unterschiede zwischen Frauen und Männern mit CED eingegangen.

Abstract

This review focuses on the gender and sex dimorphic disease profile and treatment reality of patients suffering from inflammatory bowel diseases (IBD). It provides an overview of gender-specific differences in the disease course, medical and surgical therapy as well as psychosocial aspects of IBD.

Schlüsselwörter

CED - geschlechtsspezifische Therapie

Key words

IBD - gender issues
 

  • Literatur

  • 1 Wagtmans MJ, Verspaget HW, Lamers CB et al. Gender-related differences in the clinical course of Crohn’s disease. Am J Gastroenterol 2001; 96: 1541-1546
    CrossrefPubMedGoogle Scholar
  • 2 Calkins BM, Mendeloff AI. The epidemiology of idiopathic inflammatory bowel disease. In: Kirsner JB, Shorter PG, eds Inflammatory bowel disease. 4th ed. Baltimore: Williams&Wilkins; 1995: 31-68
    Google Scholar
  • 3 Kyle J. Crohn’s disease in the northeastern and northern Isles of Scotland: an epidemiological review. Gastroenterology 1992; 103: 392-399
    CrossrefPubMedGoogle Scholar
  • 4 Latour P, Louis E, Belaiche J. Incidence of inflammatory bowel disease in the area of Liège: a 3 years prospective study (1993-1996). Acta Gastroenterol Belg 1998; 61: 410-413
    PubMedGoogle Scholar
  • 5 Shivananda S, Peña AS, Nap M et al. Epidemiology of Crohn’s disease in Regio Leiden, The Netherlands. A population study from 1979 to 1983. Gastroenterology 1987; 93: 966-974
    CrossrefPubMedGoogle Scholar
  • 6 Whelan G. Epidemiology of inflammatory bowel disease. Med Clin North Am 1990; 74: 1-12
    PubMedGoogle Scholar
  • 7 Brahme F, Lindström C, Wenckert A. Crohn’s disease in a defined population. An epidemiological study of incidence, prevalence, mortality, and secular trends in the city of Malmö, Sweden. Gastroenterology 1975; 69: 342-351
    PubMedGoogle Scholar
  • 8 Prideaux L, Kamm MA, De Cruz PP et al. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 27: 1266-80
    PubMedGoogle Scholar
  • 9 Yang SK, Loftus EV, Sandborn WJ. Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis 2001; 7: 260-270
    CrossrefPubMedGoogle Scholar
  • 10 Leong RW, Rupert WL, Lau JY et al. The epidemiology and phenotype of Crohn’s disease in the Chinese population. Inflamm Bowel Dis 2004; 10: 646-651
    CrossrefPubMedGoogle Scholar
  • 11 Ng SC, Bernstein CN, Vatn MH et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut 2013; 62: 630-649
    CrossrefPubMedGoogle Scholar
  • 12 Virta L, Auvinen A, Helenius H et al. Association of repeated exposure to antibiotics with the development of pediatric Crohn’s disease – a nationwide, register-based finnish case-control study. Am J Epidemiol 2012; 175: 775-784
    CrossrefPubMedGoogle Scholar
  • 13 Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 2010; 105: 2687-2692
    CrossrefPubMedGoogle Scholar
  • 14 Andersson RE, Olaison G, Tysk C et al. Appendectomy is followed by increased risk of Crohn’s disease. Gastroenterology 2003; 124: 40-46
    CrossrefPubMedGoogle Scholar
  • 15 Lakatos PL, Vegh Z, Lovasz BD et al. Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis 2013; 19: 1010-1017
    CrossrefPubMedGoogle Scholar
  • 16 Lakatos PL, Szamosi T, Lakatos L. Smoking in inflammatory bowel diseases: good, bad or ugly?. World J. Gastroenterol 2007; 13: 6134-6139
    CrossrefPubMedGoogle Scholar
  • 17 Bernstein CN, Blanchard JF, Rawsthorne P et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96: 1116-1122
    CrossrefPubMedGoogle Scholar
  • 18 Peyrin-Biroulet L, Loftus EV, Tremaine WJ et al. Perianal Crohn’s disease findings other than fistulas in a population-based cohort. Inflamm Bowel Dis 2012; 18: 43-48
    CrossrefPubMedGoogle Scholar
  • 19 Greenstein AJ, Sachar DB, Panday AK et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore) 1992; 71: 261-270
    CrossrefPubMedGoogle Scholar
  • 20 Wu X, Mukewar S, Kiran RP et al. Risk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease. J Crohns Colitis 2013; 7: e171-e177
    CrossrefPubMedGoogle Scholar
  • 21 Ampuero J, Rojas-Feria M, Castro-Fernández M et al. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. J Gastroenterol Hepatol 2014; 29: 291-295
    CrossrefPubMedGoogle Scholar
  • 22 Romberg-Camps MJL, Dagnelie PC, Kester AD et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009; 104: 371-383
    CrossrefPubMedGoogle Scholar
  • 23 Mazor Y, Maza I, Kaufman E et al. Prediction of disease complication occurrence in Crohn’s disease using phenotype and genotype parameters at diagnosis. J Crohns Colitis 2011; 5: 592-597
    CrossrefPubMedGoogle Scholar
  • 24 Blumenstein I, Herrmann E, Filmann N et al. Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. J Crohns Colitis 2011; 5: 203-210
    CrossrefPubMedGoogle Scholar
  • 25 Bokemeyer B, Hardt J, Hüppe D et al. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. J Crohns Colitis 2013; 7: 355-368
    CrossrefPubMedGoogle Scholar
  • 26 Høivik ML, Reinisch W, Cvancarova M et al. Anaemia in inflammatory bowel disease: a population-based 10-year follow-up. Aliment Pharmacol Ther 2014; 39: 69-76
    CrossrefPubMedGoogle Scholar
  • 27 Walldorf J, Krummerl A, Engler K et al. Health care for osteoporosis in inflammatory bowel disease: unmet needs in care of male patients?. J Crohns Colitis 2013; 7: 901-907
    CrossrefPubMedGoogle Scholar
  • 28 Wada Y, Hisamatsu T, Naganuma M et al. Risk factors for decreased bone mineral density in inflammatory bowel disease: A cross-sectional study. Clin Nutr 2015; S0261-S5614 (15)00008-4
    PubMedGoogle Scholar
  • 29 Robinson RJ, Al-Azzawi F, Iqbal SK et al. Osteoporosis and determinants of bone density patients with Crohn’s disease. Dig Dis Sci 1998; 43: 2500-2506
    CrossrefPubMedGoogle Scholar
  • 30 Bartram SA, Peaston RT, Rawlings DA et al. Multifactoral analysis of risk factors for reduced bone mineral density in patients with Crohn’s disease. World J Gastroenterol 2006; 12: 5680-5685
    CrossrefPubMedGoogle Scholar
  • 31 Ullman TA. Inflammatory bowel disease-associated cancers: does gender change incidence?. Gastroenterology 2010; 138: 1658-1660
    CrossrefPubMedGoogle Scholar
  • 32 Söderlund S, Granath F, Broström O et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology 2010; 138: 1697-1703
    CrossrefPubMedGoogle Scholar
  • 33 Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012; 10: 639-645
    CrossrefPubMedGoogle Scholar
  • 34 Bewtra M, Kaiser LM, TenHave T et al. Crohn’s disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis 2013; 19: 599-613
    CrossrefPubMedGoogle Scholar
  • 35 Lawrance IC, Willert RP, Murray K. A Validated Bowel-Preparation Tolerability Questionnaire and Assessment of Three Commonly Used Bowel-Cleansing Agents. Dig Dis Sci 2013; 58: 926-935
    CrossrefPubMedGoogle Scholar
  • 36 Bessissow T, van Keerberghen C, van Oudenhove L et al. Anxiety is associated with impaired tolerance of colonoscopy preparation in inflammatory bowel disease and controls. Journal of Crohn’s and Colitis 2013; 7: e580-e587
    PubMedGoogle Scholar
  • 37 Thukkani N, Williams LJ, Sonnenberg A. Epidemiologic characteristics of patients with inflammatory bowel disease undergoing colonoscopy. Inflamm Bowel Dis 2011; 17: 1333-1337
    CrossrefPubMedGoogle Scholar
  • 38 Koido S, Ohkusa T, Nakae K et al. Factors associated with incomplete colonoscopy at a Japanese academic hospital. World J. Gastroenterol 2014; 20: 6961-6967
    CrossrefPubMedGoogle Scholar
  • 39 Rimola J, Rodriguez S, Garcia-Bosch O et al. MR colonography in the evaluation of inflammatory bowel disease. Radiographics 2009; 29: 701-719
    CrossrefPubMedGoogle Scholar
  • 40 Shaw LJ, Shaw RE, Merz CN et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation 2008; 117: 1787-1801
    CrossrefPubMedGoogle Scholar
  • 41 Caso V, Paciaroni M, Agnelli G et al. Gender differences in patients with acute ischemic stroke. Womens Health (Lond Engl) 2010; 6: 51-57
    PubMedGoogle Scholar
  • 42 Oliver JE, Silman AJ. Why are women predisposed to autoimmune rheumatic diseases?. Arthritis Res. Ther 2009; 11: 252
    CrossrefPubMedGoogle Scholar
  • 43 Szalat A, Auryan S, Raz I et al. Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diabetes Obes Metab 2008; 10: 1135-1156
    PubMedGoogle Scholar
  • 44 Harichand-Herdt S, Ramalingam SS. Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women. Semin. Oncol 2009; 36: 572-580
    CrossrefPubMedGoogle Scholar
  • 45 Lesuis N, Befrits R, Nyberg F et al. Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med 2012; 10: 82
    CrossrefPubMedGoogle Scholar
  • 46 Peyrin-Biroulet L, Harmsen WS, Tremaine WJ et al. Surgery in a Population-Based Cohort of Crohn’s Disease From Olmsted County, Minnesota. Am J Gastroenterol 2012; 107: 1693-1701
    CrossrefPubMedGoogle Scholar
  • 47 Hofer B, Böttger T, Hernandez-Richter T et al. The impact of clinical types of disease manifestation on the risk of early postoperative recurrence in Crohn’s disease. Hepatogastroenterology 2001; 48: 152-155
    PubMedGoogle Scholar
  • 48 Targownik LE, Singh H, Nugent Z et al. The Epidemiology of Colectomy in Ulcerative Colitis: Results From a Population-Based Cohort. Am J Gastroenterol 2012; 107: 1228-1235
    CrossrefPubMedGoogle Scholar
  • 49 Samuel S, Ingle SB, Dhillon S et al. Cumulative Incidence and Risk Factors for Hospitalization and Surgery in a Population-based Cohort of Ulcerative Colitis. Inflamm Bowel Dis 2013; 19: 1858-1866
    PubMedGoogle Scholar
  • 50 Rottoli M, Remzi FH, Shen B et al. Gender of the patient may influence perioperative and long-term complications after restorative proctocolectomy. Colorectal Disease 2012; 14: 336-341
    CrossrefPubMedGoogle Scholar
  • 51 Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of Response and Need for Adalimumab Dose Intensification in Crohn’s Disease: A Systematic Review. Am J Gastroenterol 2011; 106: 674-684
    CrossrefPubMedGoogle Scholar
  • 52 Sprakes MB, Ford AC, Warren L et al. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn’s disease: A large single centre experience. Journal of Crohn’s and Colitis 2012; 6: 143-153
    PubMedGoogle Scholar
  • 53 Long MD, Drossman DA. Editorial: Inflammatory Bowel Disease, Irritable Bowel Syndrome, or What? A Challenge to the Functional–Organic Dichotomy. Am J Gastroenterol 2010; 105: 1796-1798
    CrossrefPubMedGoogle Scholar
  • 54 Chang L, Toner BB, Fukudo S et al. Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology 2006; 130: 1435-1446
    Google Scholar
  • 55 Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112: 2120-2137
    CrossrefPubMedGoogle Scholar
  • 56 Zelinkova Z, Bultman E, Vogelaar L et al. Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease. World J. Gastroenterol 2012; 18: 6967-6973
    CrossrefPubMedGoogle Scholar
  • 57 Yen L, Wu J, Hodgkins PL et al. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis. J Manag Care Pharm 2012; 18: 701-712
    PubMedGoogle Scholar
  • 58 Goodhand JR, Kamperidis N, Sirwan B et al. Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 1097-1108
    CrossrefPubMedGoogle Scholar
  • 59 Zelante A, de Giorgi A, Borgoni R et al. Adherence to medical treatment in inflammatory bowel disease patients. Minerva Gastroenterol Dietol 2014; 60: 269-274
    PubMedGoogle Scholar
  • 60 Trindade AJ, Ehrlich A, Kornbluth A et al. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis 2011; 17: 599-604
    CrossrefPubMedGoogle Scholar
  • 61 Lopez A, Billioud V, Peyrin-Biroulet C et al. Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2013; 19: 1528-1533
    CrossrefPubMedGoogle Scholar
  • 62 Long MD, Kappelman MD, Martin CF et al. Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): Methodology and initial results. Inflamm Bowel Dis 2012; 18: 2099-2106
    CrossrefPubMedGoogle Scholar
  • 63 Mantzaris GJ, Roussos A, Kalantzis C et al. How adherent to treatment with azathioprine are patients with Crohn’s disease in long-term remission?. Inflamm Bowel Dis 2007; 13: 446-450
    CrossrefPubMedGoogle Scholar
  • 64 Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis--strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008; 27: 1157-1166
    CrossrefPubMedGoogle Scholar
  • 65 López-Sanromán A, Bermejo F. Review article: how to control and improve adherence to therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 45-49
    CrossrefPubMedGoogle Scholar
  • 66 Sewitch MJ, Abrahamowicz M, Bitton A et al. Psychological distress, social support, and disease activity in patients with inflammatory bowel disease. Am J Gastroenterol 2001; 96: 1470-1479
    CrossrefPubMedGoogle Scholar
  • 67 Fuller-Thomson E, Sulman J. Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm Bowel Dis 2006; 12: 697-707
    CrossrefPubMedGoogle Scholar
  • 68 Nahon S, Lahmek P, Durance C et al. Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2086-2091
    CrossrefPubMedGoogle Scholar
  • 69 Häuser W, Janke K, Klump B et al. Anxiety and depression in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 621-632
    CrossrefPubMedGoogle Scholar
  • 70 Panara AJ, Yarur AJ, Rieders B et al. The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. Aliment Pharmacol Ther 2014; 39: 802-810
    CrossrefPubMedGoogle Scholar
  • 71 Walker JR, Ediger JP, Graff LA et al. The Manitoba IBD Cohort Study: A Population-Based Study of the Prevalence of Lifetime and 12-Month Anxiety and Mood Disorders. Am J Gastroenterol 2008; 103: 1989-1997
    CrossrefPubMedGoogle Scholar
  • 72 Maunder RG, de Rooy EC, Toner BB et al. Health-related concerns of people who receive psychological support for inflammatory bowel disease. Can J Gastroenterol 1997; 11: 681-685
    PubMedGoogle Scholar
  • 73 Graff LA, Walker JR, Lix L et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol 2006; 4: 1491-1501
    CrossrefPubMedGoogle Scholar
  • 74 Nurmi E, Haapamäki J, Paavilainen E et al. The burden of inflammatory bowel disease on health care utilization and quality of life. Scand J Gastroenterol 2013; 48: 51-57
    CrossrefPubMedGoogle Scholar
  • 75 Hauser G, Tkalcić M, Stimac D et al. Gender related differences in quality of life and affective status in patients with inflammatory bowel disease. Coll Antropol 2011; 35: 203-207
    PubMedGoogle Scholar
  • 76 McDermott E, Mullen G, Moloney J et al. Body Image Dissatisfaction. Inflamm Bowel Dis 2015; 21: 353-360
    CrossrefPubMedGoogle Scholar